Nucleai
Edit

Nucleai

https://nucleai.ai/
Last activity: 04.08.2026
Active
Categories: Artificial IntelligenceCareComputerHealthTechInformationMedtechPlatformResearchSoftwareTechnology
Join Us in Biomarker Discovery!

At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
Likes
47
Followers
3.59K
Website visits
17.8K /mo.
Mentions
12
Location: United States, Illinois, Chicago
Employees: 51-200
Total raised: $47M
Founded date: 2018

Investors 2

DateNameWebsite
09.05.2023SAV (Scale...sav.vc
-S32s32.com

Funding Rounds 2

DateSeriesAmountInvestors
04.04.2024-$14M-
23.03.2022Series B$33M-

Mentions in press and media 12

DateTitleDescription
07.08.2026AI Revolutionizes Drug Trials: QuantHealth Secures $45M to Predict SuccessQuantHealth raises $45M in Series B funding. Its AI platform simulates clinical trials. This drastically cuts drug development costs and failure rates. The technology boasts 90% predictive accuracy. It optimizes trial designs for major phar...
04.08.2026QuantHealth Raises $45M to Let Pharm Test Clinical Trials with AI Before Spending BillionsDrug development is a gamble. More than 90% of drugs that enter clinical trials fail. Three out of four of those failures are because the drug didn’t work or wasn’t safe. And by the time you find out, you’ve already spent years and hundreds...
05.04.2024Nucleai Revolutionizes Clinical Trials with $14M Funding BoostNucleai, a pioneer in spatial AI biomarkers, has secured a hefty $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA. This investment brings Nucleai's total funding to a solid $60M, fueling their mission to transform ...
04.04.2024Chicago AI-based biotech startup Nucleai raises $14 million led by M Ventures-
03.04.2024Nucleai Secures $14M to Enhance Clinical Trial Enrollment with Spatial AI BiomarkerWhat You Should Know: – Nucleai, a pioneer in spatial AI biomarkers raises $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA. – The investment brings Nucleai’s total funding to $60M and fuels their mission to transf...
03.04.2024Nucleai Raises $14M in FundingNucleai, a Chicago, IL- and Tel Aviv, Israel-based spatial AI biomarker company, raised $14M in funding. The round was led by M Ventures, and supported by existing investors. The company intends to use the funds to accelerate the deployment...
05.06.2023Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical PracticeNucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology, and Mayo Clinic BioPharma Diagnostics are pleased to announce a strategic collaboration to bring world-class digital pathology solution...
09.11.2022Nucleai Expands Scientific Advisory Board with Oncology Industry Luminary Dr. Julian AdamsNucleai, an AI-powered spatial biology leader, announced that Dr. Julian Adams has joined its scientific advisory board. Dr. Adams brings his more than 35 years of experience in oncology research and development to his role as an advisor to...
23.03.2022Nucleai Raises $33M in Series B FinancingNucleai, a Tel Aviv, Israel-based AI-powered spatial biology company, raised $33M in Series B funding. The round was led by Section 32 and Sanofi Ventures with participation from existing investors, including Debiopharm, Fosun RZ Capital, V...
22.03.2022Savings app unicorn Acorns is adding Bitcoin exposure to portfolios. Here’s the catchThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. They say a little crypto can spice up a portfolio. Paid Content How Nucor is pioneering a green f...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In